Navigation Links
Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
Date:6/1/2009

inc.com/" target="_new">www.peregrineinc.com.

Bavituximab Presentation Details:

Preliminary data from a Phase II clinical trial evaluating bavituximab in combination with docetaxel in advanced breast cancer patients will be the subject of an oral presentation at 10:30 AM EDT on June 1, 2009. A second presentation detailing preliminary results from a Phase I clinical trial evaluating bavituximab as solo therapy in patients with advanced refractory cancer will be discussed in a poster session from 1:00 PM to 5:00 PM EDT, also on June 1, 2009.

Title: Phase II study of bavituximab plus docetaxel in patients with locally advanced or metastatic breast cancer.

Authors: D. Tabagari, G. Nemsadze, M. Jincharadze, M. Janjalia, J. Shan

Time: Monday June 1, 10:30 AM

Location: Level 4, Valencia Room, W415A

Abstract No: 3005

Title: Phase I study of bavituximab, a novel anti-phosphatidylserine monoclonal antibody in patients with advanced refractory cancer: Preliminary results.

Authors: N. K. Ibrahim, L. Wong, L. Rosen, J. Shan

Time: Monday June 1, 1:00 PM to 5:00 PM

Location: Level 2, West Hall C

Abstract No: 1080

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information ab
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
2. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
3. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
4. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
5. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
6. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
7. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
8. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
9. Peregrine Pharmaceuticals Enters Into a Loan Agreement for up to $10 Million
10. Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results
11. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... registered accounting firm, Ernst & Young LLP ("EY") that it ... in a letter delivered to the Company on September 15, ... 16, 2014.  PDL has issued the following ... received a number of inquiries on the reason for the ...
(Date:9/17/2014)... 17, 2014 A long-term retrospective study ... irradiation (APBI) via interstitial brachytherapy suggests that women ... nodes could be suitable to receive the treatment. ... place these patients in the "unsuitable" category for ... ASTRO meeting, Beaumont Health System,s Peter Y. ...
(Date:9/17/2014)... 17, 2014 The global consumption of squalene / ... is a natural skin-identical chemical that finds applications in various ... supplements, pharmaceuticals, and in other applications like high grade lubrication, ... a few major players and is regionally segregated. Sophim ( ... Oil Co. Ltd. ( Japan ), SeaDragon Marine ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 2Squalene Market by Source (Animal & Vegetable) & by End-user Industry (Cosmetics, Pharmaceuticals & Food Industry) - Global Trends & Forecasts to 2019 3Oncothyreon Announces Proposed Public Offerings 2
... flies that spend a day buzzing around the "fly mall" ... makes their brain circuits grow dense new synapses and they ... stimulated brains, according to a new study by UW- Madison ... number of synapses -- the junctions between nerve cells where ...
... Biosciences, Inc. (NASDAQ: NBIX ) announced today that ... a Notice of Allowance for the Company,s proprietary Vesicular Monoamine ... that a composition of matter patent on NBI-98854 will have ... Additionally, on June 17, 2011, the Company held a ...
... test to detect the levels of vitamin B12 using your ... could help to avoid the potentially fatal symptoms of B12 ... 2011, in IOP Publishing,s Journal of Breath Research , ... more accurately measure vitamin B12. Vitamin B12 deficiency ...
Cached Biology Technology:New study: Even in flies, enriched learning drives need for sleep 2Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 2Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 3A breath of fresh air for detecting vitamin B12 deficiency 2
(Date:9/17/2014)... about complex social behavior by studying nonhuman mammals and ... , With their unusually large brains relative to their ... complex social environment---not merely in a large population of ... a dynamic setting of alliances and competitors. The same ... primates, and social carnivores, like hyenas and lions. , ...
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2
... of Sheffield have applied an evolutionary ,use it or ... show that marriage can influence the evolution of age-patterns ... and Dr Andrew Russell, from the University,s Department of ... the 18th and 19th centuries, a time during which ...
... Using satellite data, scientists have produced a first-of-its kind map ... are other local- and regional-scale forest canopy maps, the new ... on one uniform method. The map, based on data ... scientists build an inventory of how much carbon the world,s ...
... University of California, Riverside biologists working on guppies ... long-term studies report that rapid growth responses to ... early in life have repercussions in adulthood. Based ... that grew rapidly as juveniles produced fewer offspring than ...
Cached Biology News:Marriage patterns drive fertility decline 2First-of-its-kind map details the height of the globe's forests 2Rapid growth in adolescence leads to fewer offspring, UC Riverside biologists find 2Rapid growth in adolescence leads to fewer offspring, UC Riverside biologists find 3
The Light Diagnostics Calicivirus Genotype 1&2 Typing OligoDetect assay is applicable for the qualitative detection of calicivirus RNA generated by an in-house validated in vitro nucleic acid amplifi...
X-Gal...
Recombinant Rat CINC-2 alpha, CF...
RABBIT ANTI SRC-RSV...
Biology Products: